Domestic Biomaterials Industry Needs Stronger Commercialization Support Beyond R&D
- Input
- 2026-11-19 10:35:27
- Updated
- 2026-11-19 10:35:27

The Korea Biotechnology Industry Organization (KBIO) said on the 19th that it had published a report titled “Paradigm Shift in the Sustainable Biomaterials Industry and Policy Recommendations,” which analyzes domestic and international industry trends and company cases and outlines ways to strengthen industrial competitiveness and promote commercialization.
Biomaterials are materials made using biological resources such as plants, microorganisms and proteins. They are used across a range of industries, including food, cosmetics and agriculture. Recently, the development and production of these materials have also changed as AI, synthetic biology and biomanufacturing technologies have been brought to bear.
The report identified the gap between research and development outcomes and commercialization as a key challenge for South Korea’s biomaterials industry. Although support for technology development and commercialization is expanding, support at the demonstration and production scale-up stages remains important to help companies manufacture actual products and enter the market.
To address this, the organization proposed six policy priorities: standardizing biomaterial raw materials and building supply chains; upgrading market-demand-based industrialization support systems; expanding demonstration and scale-up infrastructure; improving regulatory and evaluation systems for new types of biomaterials; building an AI-based innovation ecosystem for biomaterials; and fostering investment and the broader industrial ecosystem.
The report particularly emphasized the need to expand joint research and development and proof-of-concept (PoC) projects involving demand-side companies from the early stages of technology development. It said support should reflect the needs of actual industrial sites from the development stage onward, with a phased support system extending from material performance testing through production scale-up to final product development.
Oh Gi-hwan, director of KBIO’s Bioeconomy Research Center, said, “Biomaterials are increasingly being used across a range of industries, including food, cosmetics and agriculture, and industrial opportunities are also expanding with advances in AI and biomanufacturing technologies.” He added, “Policy efforts are needed to link collaboration with demand-side companies, demonstration and scale-up infrastructure, and regulatory and investment support so that domestic companies can turn the technologies they have developed into actual products and businesses.”
[email protected] Jung Sang-hee Reporter